Year-end Sale % OFF 
Abstract
Twelve phosphonopropionates derived from 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid (3-IPEHPC) were synthesized and evaluated for their activity as inhibitors of protein geranylgeranylation. The nature of the substituent in the C6 position of imidazo[1,2-a]pyridine ring was responsible for the compound's activity against Rab geranylgeranyl transferase (RGGT). The most active inhibitors disrupted Rab11A prenylation in the human cervical carcinoma HeLa cell line. The esterification of carboxylic acid in the phosphonopropionate moiety turned the inhibitor into an inactive analog.
Highlights
Rab geranylgeranyl transferase (RGGT) constitutes a potential therapeutic target, as it is responsible for posttranslational prenylation of Rab GTPases (Kelly et al, 2012)
We have previously demonstrated that phosphonocarboxylates with imidazo[1,2-a]pyridine ring substituted in the C6 position of the heterocycle show activity toward RGGT (Kazmierczak et al, 2017)
We synthesized a set of 12 new phosphonocarboxylate derivatives of a previously described potent RGGT inhibitor, namely 3-IPEHPC (McKenna et al, 2010; Błazewska et al, 2011)
Summary
Rab geranylgeranyl transferase (RGGT) constitutes a potential therapeutic target, as it is responsible for posttranslational prenylation of Rab GTPases (Kelly et al, 2012). The analogs bearing C3-substituted pyridine (Coxon et al, 2001; Marma et al, 2007; Baron et al, 2009) and Nsubstituted benzimidazole (Bhuiyan et al, 2019) are less active against RGGT, the latter were tested only as the socalled desoxy analogs, which are known to be less active than Cαfluorinated analogs (Marma et al, 2007; Coxon et al, 2014). As these compounds bear two ionic groups, we have undertaken the effort to synthesize their prodrug analogs. Besides the varied character of substituents in terms of bulkiness, length, and geometry, we studied the influence of the basic and acidic nature of introduced groups on the activity of these compounds against RGGT
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
